← Browse by Condition
Medical Condition

cerebral infarction

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 3

ClinicalMetric tracks all active clinical trials for cerebral infarction sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — cerebral infarction Clinical Trials

How many clinical trials are currently recruiting for cerebral infarction?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for cerebral infarction, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for cerebral infarction?
cerebral infarction research spans Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a cerebral infarction clinical trial?
Eligibility criteria for cerebral infarction trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 3
2
Top Sponsors
MD Stem Cells 1 trial
Assistance Publique - Hôpitaux de Paris 1 trial
Weifang Medical University 1 trial

Recruiting Clinical Trials

NCT02795052
Recruiting
Neurologic Stem Cell Treatment Study
Enrollment
500 pts
Location
United States, Unite...
Sponsor
MD Stem Cells
View Trial →
NCT05476991 Phase 3
Recruiting
Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis
Enrollment
2,800 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux...
View Trial →
NCT07379190 Phase 3
Recruiting
HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN)
Enrollment
458 pts
Location
China
Sponsor
Weifang Medical University
View Trial →

Related Conditions

stroke (2) stroke ischemic (2) neurologic disorders (1) nervous system diseases (1) neurodegenerative diseases (1) neurological disorders (1) traumatic brain injury (1) cadasil (1) chronic traumatic encephalopathy (1) cerebral ischemia (1) cerebral stroke (1) cerebral hemorrhage (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology